Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6845

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Head and Neck Cancer
Interventions: cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2031
U.S. locations: 259
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 196 more

Conditions: Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
Interventions: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Radiation Therapy, Thioguanine, Vincristine, Vincristine Sulfate; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 188
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more

Conditions: Lumbosacral Radiculopathy
Interventions: VER-01, Placebo; Drug · Other
Lead sponsor: Vertanical GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Mobile, Alabama • Tempe, Arizona • Long Beach, California + 19 more

Conditions: Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions: Xanamem, Placebo; Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more

Conditions: Crohn's Disease
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 127
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 107 more

Conditions: Advanced Solid Tumors
Interventions: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 862 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 28
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more

Conditions: Hepatocellular Carcinoma
Interventions: BAY 3547926, BAY 3547922, BAY 3713391, BAY 3713389; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Dothan, Alabama • Duarte, California • Orlando, Florida + 1 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more

Conditions: Leukemia
Interventions: cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 59 Years
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 170
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more

Conditions: Heart Failure
Interventions: Baxdrostat and dapagliflozin, Placebo and dapagliflozin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 11,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 217
States / cities: Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more

Conditions: Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: Barostim System, Usual care medical management; Device · Other
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 20
States / cities: Mobile, Alabama • Los Angeles, California • Clearwater, Florida + 16 more

Conditions: Colitis, Ulcerative
Interventions: Low-dose MH002, High-dose MH002, Placebo; Drug
Lead sponsor: MRM Health NV; Industry
Eligibility: 16 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

Confirmatory Clinical Study in Active Ulcerative Colitis